Evidence map›Paper›PMID 38204245›Full record

ArticleCurrent stem cell research & therapy2024

Fucoxanthin Enhances the Antifibrotic Potential of Placenta-derived Mesenchymal Stem Cells in a CCl4-induced Mouse Model of Liver.

Vasilii Slautin, Konstantin Konyshev, Ilya Gavrilov, Olga Beresneva, Irina Maklakova, Dmitry Grebnev

Abstract read
PubMed Publisher
In one paragraph

Article in Current stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vasilii SlautinDepartment of Pathophysiology , Ural State Medical University, 3, Repin Street, 620028, Yekaterinburg, Russia.ORCID 0000-0003-3967-0442
Konstantin KonyshevDepartment of Pathophysiology , Ural State Medical University, 3, Repin Street, 620028, Yekaterinburg, Russia.ORCID 0000-0002-9816-0007
Ilya GavrilovDepartment of Pathophysiology , Ural State Medical University, 3, Repin Street, 620028, Yekaterinburg, Russia.ORCID 0000-0003-0806-1177
Olga BeresnevaDepartment of Pathophysiology , Ural State Medical University, 3, Repin Street, 620028, Yekaterinburg, Russia.ORCID 0000-0003-4272-7622
Irina MaklakovaDepartment of Pathophysiology , Ural State Medical University, 3, Repin Street, 620028, Yekaterinburg, Russia.ORCID 0000-0002-6895-7947
Dmitry GrebnevDepartment of Pathophysiology , Ural State Medical University, 3, Repin Street, 620028, Yekaterinburg, Russia.ORCID 0000-0002-5698-8404

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effectiveness of fucoxanthin (Fx) in liver diseases has been reported due to its anti-inflammatory and antifibrotic effects. Mesenchymal stem cells (MSCs)-based therapy has also been proposed as a promising strategy for liver fibrosis treatment. Recent studies have shown that the co-administration of MSCs and drugs demonstrates a pronounced effect on liver fibrosis.

aimThis study aimed to determine the therapeutic potential of placenta-derived MSCs (PD-MSCs) in combination with Fx to treat liver fibrosis and evaluate their impact on the main links of liver fibrosis pathogenesis.

methodsAfter PD-MSCs isolation and identification, outbred ICR/CD1 mice were divided into five groups: Control group, CCl

resultsCompared to the single treatment with PD-MSCs or Fx, their combined administration significantly reduced liver enzyme activity, the severity of liver fibrosis, the proinflammatory cytokine levels, TGF-β level, α-SMA+, TIMP-1+ areas and the number of positive cells in them, and increased HGF level, MMP-13+, and MMP-9+ areas.

conclusionFx enhanced the therapeutic potential of PD-MSCs in CCl4-induced liver fibrosis, but more investigations are necessary to understand the mutual impact of PD-MSCs and Fx.

Indexed as

Carbon TetrachlorideDisease Models, AnimalLiver CirrhosisMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPlacentaTissue Inhibitor of Metalloproteinase-1XanthophyllsActinsAnimalsFemaleHepatocyte Growth FactorLiverMaleMatrix Metalloproteinase 13Matrix Metalloproteinase 9ActinsCarbon TetrachloridefucoxanthinHepatocyte Growth FactorHGF protein, mouseMatrix Metalloproteinase 13Matrix Metalloproteinase 9Mmp13 protein, mouseMmp9 protein, mouseTgfb1 protein, mouseTimp1 protein, mouseTissue Inhibitor of Metalloproteinase-1Transforming Growth Factor betaTransforming Growth Factor beta1Xanthophyllsfucoxanthinhepatic stellate cellsLiver fibrosisMSCs-based therapyplacenta-derived mesenchymal stem cellsTGF-β.

Identifiers

PMID38204245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.